H.C. Wainwright Reiterates Neutral Rating on Entrada Therapeutics (TRDA)

October 19, 2026 7:59 AM EDT Send to a Friend
H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Neutral rating on Entrada Therapeutics (NASDAQ: TRDA).The analyst commented: "ENTR-601-45 shows favorable initial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login